TFC Financial Management Inc. Sells Shares of Johnson & Johnson (NYSE:JNJ)

Investment Update: TFC Financial Management Inc. Decreases Holdings in Johnson & Johnson

Are you interested in learning more about one of the most well-known companies in the healthcare field? Johnson & Johnson (NYSE:JNJ) has been making headlines recently, and for good reason. TFC Financial Management Inc. recently decreased its holdings in the company, sparking interest among investors and analysts alike.

In the first quarter, TFC Financial Management Inc. sold 117 shares of Johnson & Johnson, bringing its total holdings to 53,898 shares worth $8,526,000. Despite this decrease, Johnson & Johnson remains a significant player in the investment portfolio, making up approximately 1.5% of TFC Financial Management Inc.’s holdings.

But TFC Financial Management Inc. isn’t the only one making moves with Johnson & Johnson. Other institutional investors have also been active, with Norges Bank acquiring a new position in the company valued at over $4 billion. Wellington Management Group LLP and International Assets Investment Management LLC have also increased their stakes in Johnson & Johnson, showing confidence in the company’s future performance.

In terms of price performance, Johnson & Johnson has seen its stock fluctuate between a one year low of $143.13 and a high of $175.97. With a market cap of $352.53 billion and a P/E ratio of 9.13, Johnson & Johnson continues to be a strong player in the healthcare industry.

The company recently reported its quarterly earnings, beating expectations with $2.71 EPS. Analysts expect Johnson & Johnson to post 10.62 earnings per share for the current year, showing promising growth potential.

In addition, Johnson & Johnson recently increased its quarterly dividend, providing investors with a $1.24 dividend and a dividend yield of 3.39%. This represents a 30.92% dividend payout ratio, showcasing the company’s commitment to rewarding shareholders.

Wall Street analysts have weighed in on Johnson & Johnson, with a consensus rating of “Moderate Buy” and an average price target of $174.07. With several analysts giving positive ratings and price targets, Johnson & Johnson continues to be a strong contender in the healthcare sector.

If you’re interested in learning more about Johnson & Johnson and its recent developments, be sure to check out the latest report on JNJ. With its innovative products and strong financial performance, Johnson & Johnson remains a top choice for investors looking for stability and growth in the healthcare industry.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.